HCC and Molecular Targeting Therapies: Back to the Future.

Biomedicines · 2021 · PMC8533575 · PMID 34680462

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Although the difference in overall survival in the lenvatinib group and the sorafenib group did not reach statistical significance, the progression-free survival (PFS) of the lenvatinib group was twice that of the sorafenib group and the time to progression was almost 3 times longer than in the sorafenib group [ 64 ].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.